🚨🚨 #Adagrasib 🎯🎯 in patients with #KRAS G12C mutations; tumor agnostic (Non-CRC, Non-NSCLC). ➡️ Median 2 lines of prior therapy ➡️ All Patients: ORR 35%; Median PFS 7.4 months; OS: 14 months ➡️ PDAC ORR 33.3%; DCR: 81% ➡️BTC ORR 42.7%; DCR : 91.7%

Just getting a hang of the data from #ASH25 and #SABCS25 — But #GI26 is upon us! Let’s 🗣️ how #GI26 will change our practice/SoC! ⭐️InPerson: Jan 9, 2026 ⭐️Time: 6:30-8:30PM - Panc-Biliary - Upper GI - CRC & NET ⭐️Register https://t.co/d7kIBwJq3s #OncTwitter @OncoAlert

Dynamic Discussions on RAS Biology, RAS in NSCLC and GI Cancers at @myESMO Asia 2025 - @DrShubhamPant https://t.co/ENmuxrg2TP #Cancer #Medicine #Health #Oncology #OncoDaily #ESMOAsia25 #MedX #MedNews #MedEd

🧬Looking to learn about AE management & pancreatic cancer care? Master frontline selection, sequencing, and AE management for metastatic pancreatic cancer with experts @DrShubhamPant & @lwumd323 Earn free CME credits with this on-demand activity! 👉 https://t.co/ihlJBcQ722

Going to #GI26? Let’s 🗣️ the current SoC & how #GI26 will change/reinforce our practice! InPerson Jan 9, 2026 w/ @DrShubhamPant @CentralParkWMD @DrR_DUNNE @rutikamehtaMD @AnwaarSaeed3 @NVijayvergiaMD Register https://t.co/d7kIBwJXT0 #gism #OncTwitter @OncoAlert

Final results from the HERIZON-BTC-01 clinical trial show zanidatamab delivered clinically meaningful and durable responses for patients with HER2 positive biliary tract cancer. Learn more about this new research: https://t.co/kXjT7shgBK @DrShubhamPant #EndCancer

In this interview, @DrShubhamPant and @ryanhuey of @MDAndersonNews explain how inhibiting the OXPHOS pathway with lixumistat could suppress cancer cell growth and decrease resistance to available therapies in #pancreaticcancer. Learn more 📰:

Targeting OXPHOS With Lixumistat Could Lessen Chemoresistance in Pancreatic Cancer @MDAndersonNews @DrShubhamPant @ryanhuey #oncology #pancreaticcancer https://t.co/PCFdk8eTSZ

Had the opportunity to moderate and present at the Chemotherapy Foundation Symposium on RAS-altered cancers in an interactive “hot seat” format. Gr8 discussion on emerging strategies for RAS-driven lung, gynecologic & GI cancers!! @gotoPER #CFS @MJHLifeSciences

GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) @DrShubhamPant & Prof. @efratdotan discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of

Had a Gr8 discussion with @rachnatshroff on one of my fav topics: Molecular Profiling in Pancreatic Cancer, with a deep dive into RAS testing and codon-specific interpretation!! 💥 Watch this space—more discussions and insights to come!!! https://t.co/c6tmdEO3pf via @onclive

mPDAC is notoriously aggressive with a poor prognosis. Most patients are diagnosed at an advanced stage and need chemotherapy as soon as possible. In this podcast, Profs. @DrShubhamPant & @efratdotan discuss how to select and optimise first- and second-line chemotherapeutic

Hear @DrShubhamPant and @rachnatshroff discuss how KRAS mutations, long considered “undruggable” in pancreatic cancer, are now emerging as actionable targets, offering new hope for a historically treatment-resistant disease. Watch more here!

@DrShubhamPant kicks off session on clinical data with RAS inhibitors - VERY promising early data! #DAVAGI

🧵 Encouraging early results from @ElicioTx KRAS-targeting vaccine in #pancreaticcancer and colorectal cancer published in @NatureMedicine, feat. co-corresponding authors/@PanCAN SMAB members @DrShubhamPant and @EileenMOReilly. https://t.co/8l86hmcfVO

🔎 mPDAC is notoriously aggressive w/ a poor prognosis Patients are generally Dx’d w/ advanced-stage disease & require chemotherapy as soon as possible New podcast episode from Prof. @DrShubhamPant and Prof. @efratdotan! 📹 Highlights video in this post Listen to the full

Received a Texas sized farewell from my @MDAndersonNews family, complete with an exceptional brisket from top chef @eugenekoay. Thanks to Stacy & Eugene for hosting and the gang for 12 AMAZING years of friendship & collaboration (both keep going!) Grateful to all of you 🙏🏽🙏🏽

Frontline Tx regimens in mPDAC should be individualised based on: 🔸performance status 🔸comorbidities 🔸risk of neuropathy 👉 FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles What else do HCPs need to know about

Had a Gr8 discussion with @rachnatshroff on one of my fav topics: Molecular Profiling in Pancreatic Cancer, with a deep dive into RAS testing and codon-specific interpretation!! 💥 Watch this space—more discussions and insights to come!!! https://t.co/c6tmdEO3pf via @onclive

@TumorBoardTues @DrShubhamPant @MPishvaian @drsmags @NeehaZaidi @rohit_thum @GIMedOnc @ShrutiPatelMD @ryanhuey @SaumyaMaruMDPhD @MadhuEluri @ebludmir @DanZhaoMD @GIcancerDoc @CentralParkWMD @marklewismd @Aiims1742 @ArndtVogel @OncBrothers 18/18 #TumorBoardTuesday 🎯Key takeaways, cont’d: 💰Financial toxicity of NALIRIFOX = major concern 💩Caution re: increased risk of GI side effects (diarrhea, n/v) 💡May consider NALIRIFOX in select pts due to ⬇️neuropathy + BM suppression

@TumorBoardTues @DrShubhamPant @MPishvaian @drsmags @NeehaZaidi @rohit_thum @GIMedOnc @ShrutiPatelMD @ryanhuey @SaumyaMaruMDPhD @MadhuEluri @ebludmir @DanZhaoMD @GIcancerDoc @CentralParkWMD @marklewismd @Aiims1742 @ArndtVogel @OncBrothers 7/18 #TumorBoardTuesday 🌍 NAPOLI-3: randomized, open-label, global Ph3 trial (n=770) @LancetOncol ⚖️ NALIRIFOX > Gem+nab-P in 1L metastatic PDAC 🟢 Median OS: 11.1 mos 🆚 9.2 mos (HR 0.83; p=0.036) 🟢 Median PFS: 7.4 mos 🆚 5.6 mos (HR 0.70; p<0.0001) 🟡 ORR: 41.8%